The United Kingdom and the United States have reached a key trade agreement that will maintain zero import taxes on UK drug exports entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these key goods will be held at nothing for a duration of three years.
This deal comes after earlier threats to hike tariffs on patented pharmaceutical imports, with figures discussed reaching double the cost.
"This deal with the UK strengthens the global environment for innovative medicines and brings much-needed equity to transatlantic medicine commerce," an announcement noted.
Economic Significance
Pharmaceuticals represent one of the the United Kingdom's most significant goods shipped to the United States, which is by far the biggest buyer for major British pharmaceutical firms.
Trade data reveal that in the year prior to the third quarter, the UK sold drugs totaling over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This guarantee protects work, boosts funding and sets the stage for the UK to become a international leader for life sciences," a minister stated.
Detailed NHS Changes
The pact includes several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. In the past, repayments topped 20%.
Industry Background
The pact comes amid a ongoing row between the pharmaceutical industry and the UK government over drug pricing and approval rates.
These tensions were exacerbated by arguments that US customers were paying significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the last ten years.
